Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes

Sylwia Wasiak; Dean Gilham; Laura M Tsujikawa; Christopher Halliday; Karen Norek; Reena G Patel; Kevin G McLure; Peter R Young; Allan Gordon; Ewelina Kulikowski; Jan Johansson; Michael Sweeney; Norman C Wong

doi:10.1016/j.dib.2016.07.047

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes

Data Brief. 2016 Jul 29:8:1280-8. doi: 10.1016/j.dib.2016.07.047. eCollection 2016 Sep.

Affiliations

¹ Resverlogix Corp., Calgary, Canada.
² Resverlogix Corp., San Francisco, USA.

Abstract

Apabetalone (RVX-208) inhibits the interaction between epigenetic regulators known as bromodomain and extraterminal (BET) proteins and acetyl-lysine marks on histone tails. Data presented here supports the manuscript published in Atherosclerosis "RVX-208, a BET-inhibitor for Treating Atherosclerotic Cardiovascular Disease, Raises ApoA-I/HDL and Represses Pathways that Contribute to Cardiovascular Disease" (Gilham et al., 2016) [1]. It shows that RVX-208 and a comparator BET inhibitor (BETi) JQ1 increase mRNA expression and production of apolipoprotein A-I (ApoA-I), the main protein component of high density lipoproteins, in primary human and African green monkey hepatocytes. In addition, reported here are gene expression changes from a microarray-based analysis of human whole blood and of primary human hepatocytes treated with RVX-208.

Keywords: African green monkey; ApoA-I; Apolipoprotein A-I; BET inhibitor; BET proteins; Bromodomain; Gene expression; JQ1; Microarrays; Primary human hepatocytes; RVX-208; Vascular inflammation.